Tumor Type: Brain
Metastasis
IRB Approval: 11/11/2008
RTOG 0614: A Randomized, Phase III, Double-Blind, Placebo-Controlled
Trial of Memantine for Prevention of Cognitive Dysfunction in
Patients Receiving Whole Brain Radiotherapy
The
primary objective is to determine the addition of Memantine to
WBRT preserves cognitive function, specifically memory over that
of placebo and WBRT in patients with brain metastases.
| Inclusion Criteria: |
Solid tumor malignancy and brain metastases
Controlled primary disease for 3 months+
Chemotherapy completed > 14 days |
| Exclusion Criteria: |
Prior
cranial radiation
MI
within last 6 months |
| Treatment: |
Arm 1: WBRT/15
fractions + Memantine
Arm 2: WBRT/15
fractions + placebo |
| Principle Investigator: |
Rajesh Iyer, MD
Radiation
Oncology
Community
Medical Center
99
Route 37 West
Toms
River, New Jersey 08755
(732)
557-8148 |
| Study Site Coordinator: |
Debbie Moriarty, RN, MSN, OCN
Community
Medical Center
99
Route 37 West
Toms
River, New Jersey 08755
(732)557-8294 |
[ open protocol list ] [ top ] |
|
|
